BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND DDX6, P54, 1656, ENSG00000110367, HLR2, P26196, RCK, FLJ36338 AND Treatment
9 results:

  • 1. Reconstruction of clone- and haplotype-specific cancer genome karyotypes from bulk tumor samples.
    Aganezov S; Raphael BJ
    Genome Res; 2020 Sep; 30(9):1274-1290. PubMed ID: 32887685
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
    Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
    Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Parkinson's disease and risk of prostate cancer: A Danish population-based case-control study, 1995-2010.
    Jespersen CG; Nørgaard M; Borre M
    Cancer Epidemiol; 2016 Dec; 45():157-161. PubMed ID: 27838564
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Comparing High-Intensity Focal Ultrasound Hemiablation to Robotic Radical prostatectomy in the Management of Unilateral prostate cancer: A Matched-Pair Analysis.
    Albisinni S; Aoun F; Bellucci S; Biaou I; Limani K; Hawaux E; Peltier A; van Velthoven R
    J Endourol; 2017 Jan; 31(1):14-19. PubMed ID: 27799004
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.
    Amaral CL; Freitas LB; Tamura RE; Tavares MR; Pavan IC; Bajgelman MC; Simabuco FM
    BMC Cancer; 2016 Aug; 16():602. PubMed ID: 27491285
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with prostate cancer Treated with Radical prostatectomy.
    Boehm K; Larcher A; Tian Z; Mandel P; Schiffmann J; Karakiewicz PI; Graefen M; Huland H; Tilki D
    J Urol; 2016 Jul; 196(1):82-8. PubMed ID: 26925872
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. ddx6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.
    Iio A; Takagi T; Miki K; Naoe T; Nakayama A; Akao Y
    Biochim Biophys Acta; 2013 Oct; 1829(10):1102-10. PubMed ID: 23932921
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
    Noguchi M; Moriya F; Suekane S; Matsuoka K; Arai G; Matsueda S; Sasada T; Yamada A; Itoh K
    Prostate; 2012 Jun; 72(8):834-45. PubMed ID: 21932426
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence.
    Pettaway CA; Lamerato LE; Eaddy MT; Edwards JK; Hogue SL; Crane MM
    BJU Int; 2011 Oct; 108(8):1302-8. PubMed ID: 21371244
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.